Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Andrews

Showing results (731-740 of 754) with videos related to

Pageof 76
Sort By:
Journal of Medicinal Chemistry|January 15, 2015
Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK)Adrian L Smith, Kristin L Andrews, Holger Beckmann, et al.
The Journal of Biological Chemistry|December 24, 2002
The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acidsCelia P Briscoe, Mohammad Tadayyon, John L Andrews, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2016
Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitorsRyan P Wurz, Christine Sastri, Derin C D'Amico, et al.
Bioorganic & Medicinal Chemistry|December 3, 2014
Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubilityRobert M Rzasa, Michael J Frohn, Kristin L Andrews, et al.
Journal of the American College of Cardiology|December 28, 2010
Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervalsIlan Goldenberg, Samuel Horr, Arthur J Moss, et al.
Bioorganic & Medicinal Chemistry Letters|January 21, 2015
The discovery and optimization of aminooxadiazoles as potent Pim kinase inhibitorsRyan P Wurz, Liping H Pettus, Claire Jackson, et al.
Circulation|August 28, 2016
Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter StudyArthur A M Wilde, Arthur J Moss, Elizabeth S Kaufman, et al.
Molecular Cancer Therapeutics|April 2, 2020
Biophysical and Immunological Characterization and <i>In Vivo</i> Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody PembrolizumabBeth Hutchins, Gary C Starling, Mark A McCoy, et al.
Journal of Medicinal Chemistry|January 11, 2014
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-conceptKate S Ashton, Kristin L Andrews, Marian C Bryan, et al.
ACS Medicinal Chemistry Letters|April 21, 2016
Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase InhibitorsVictor J Cee, Frank Chavez, Bradley Herberich, et al.
Pageof 76

Showing results (731-740 of 754) with videos related to

Sort By:
Pageof 76
Journal of Medicinal Chemistry|January 15, 2015
Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK)Adrian L Smith, Kristin L Andrews, Holger Beckmann, et al.
The Journal of Biological Chemistry|December 24, 2002
The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acidsCelia P Briscoe, Mohammad Tadayyon, John L Andrews, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2016
Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitorsRyan P Wurz, Christine Sastri, Derin C D'Amico, et al.
Bioorganic & Medicinal Chemistry|December 3, 2014
Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubilityRobert M Rzasa, Michael J Frohn, Kristin L Andrews, et al.
Journal of the American College of Cardiology|December 28, 2010
Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervalsIlan Goldenberg, Samuel Horr, Arthur J Moss, et al.
Bioorganic & Medicinal Chemistry Letters|January 21, 2015
The discovery and optimization of aminooxadiazoles as potent Pim kinase inhibitorsRyan P Wurz, Liping H Pettus, Claire Jackson, et al.
Circulation|August 28, 2016
Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter StudyArthur A M Wilde, Arthur J Moss, Elizabeth S Kaufman, et al.
Molecular Cancer Therapeutics|April 2, 2020
Biophysical and Immunological Characterization and <i>In Vivo</i> Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody PembrolizumabBeth Hutchins, Gary C Starling, Mark A McCoy, et al.
Journal of Medicinal Chemistry|January 11, 2014
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-conceptKate S Ashton, Kristin L Andrews, Marian C Bryan, et al.
ACS Medicinal Chemistry Letters|April 21, 2016
Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase InhibitorsVictor J Cee, Frank Chavez, Bradley Herberich, et al.
Pageof 76